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Background. The human immunodeficiency virus type 1 reverse-transcriptase mutation K65R is a single-point
mutation that has become more frequent after increased use of tenofovir disoproxil fumarate (TDF). We aimed
to identify predictors for the emergence of K65R, using clinical data and genotypic resistance tests from the Swiss
HIV Cohort Study.
Methods. A total of 222 patients with genotypic resistance tests performed while receiving treatment with
TDF-containing regimens were stratified by detectability of K65R (K65R group, 42 patients; undetected K65R
group, 180 patients). Patient characteristics at start of that treatment were analyzed.
Results. In an adjusted logistic regression, TDF treatment with nonnucleoside reverse-transcriptase inhibitors
and/or didanosine was associated with the emergence of K65R, whereas the presence of any of the thymidine
analogue mutations D67N, K70R, T215F, or K219E/Q was protective. The previously undescribed mutational
pattern K65R/G190S/Y181C was observed in 6 of 21 patients treated with efavirenz and TDF. Salvage therapy after
TDF treatment was started for 36 patients with K65R and for 118 patients from the wild-type group. Proportions
of patients attaining human immunodeficiency virus type 1 loads !50 copies/mL after 24 weeks of continuous
treatment were similar for the K65R group (44.1%; 95% confidence interval, 27.2%–62.1%) and the wild-type
group (51.9%; 95% confidence interval, 42.0%–61.6%).
Conclusions. In settings where thymidine analogue mutations are less likely to be present, such as at start of
first-line therapy or after extended treatment interruptions, combinations of TDF with other K65R-inducing
components or with efavirenz or nevirapine may carry an enhanced risk of the emergence of K65R. The finding
of a distinct mutational pattern selected by treatment with TDF and efavirenz suggests a potential fitness interaction
between K65R and nonnucleoside reverse-transcriptase inhibitor–induced mutations.
The nucleoside reverse-transcriptase inhibitor (NRTI)
tenofovir disoproxil fumarate (TDF) has become an
important component of HIV combination therapy in
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Switzerland because of its potency and once-daily dos-
ing [1, 2]. However, emergence of resistance and viral
breakthrough can occur quickly, such as when TDF is
used in combination with didanosine (ddI) and efa-
virenz (EFV) [3–5] or with abacavir (ABC) and lami-
vudine (3TC) [6]. The key mutation for resistance
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against TDF is a lysinerarginine switch at position 65 in the
reverse-transcriptase (RT) gene (i.e., K65R), which requires
only 1 nucleotide base change [7, 8]. But contrary to other
single-point mutations inducing HIV drug resistance, such as
the RT mutation M184V, the prevalence of K65R in TDF-
exposed individuals is limited, rarely 12%, despite the wide-
spread use of TDF and other drugs, such as ABC and ddI [9,
10], that also select for K65R. Some increases in the prevalence
of K65R may, however, have occurred in recent years [11, 12].
Thymidine analogue mutations (TAMs) selected by zido-
vudine or stavudine counteract the selection of the K65R mu-
tation, as shown both in vitro [13] and in patients [10, 12, 14,
15]. Parikh et al. [16] elucidated the biochemical mechanisms
and further demonstrated that TAMs and K65R do not appear
on the same viral genome because of competing mutational
pathways [17]. In contrast, inclusion of TDF in first-line ther-
apy [2, 18, 19] or combination therapy with TDF and ddI [14,
20] promotes the emergence of K65R. Our aim was to confirm
and extend current knowledge about baseline predictors for the
K65R mutation and to identify mutational correlates.
METHODS
Data and patient selection. Our analysis included clinical and
genotypic data collected until July 2007. The Swiss HIV Cohort
Study (SHCS) is a nationwide, clinic-based cohort study with
continuous enrollment and semiannual study visits [21]. The
SHCS has been approved by ethical committees of all partic-
ipating institutions, and written informed consent was obtained
from participants. The SHCS resistance database contains all
genotypic HIV resistance tests performed by the 4 authorized
laboratories in Switzerland, stored in SmartGene’s (Zug, Swit-
zerland) Integrated Database Network System (IDNS, version
3.4.0) [22].
The database was screened for resistance tests performed
from January 2002 through July 2007 for patients receiving
treatment with TDF or 30 days after end of treatment. Be-
cause tests were obtained under various circumstances (e.g., at
therapy initiation or in salvage settings), we further restricted
selection to reduce confounding. First, we excluded samples
from patients who had previously experienced a virological
failure during treatment with TDF, ABC, or ddI without re-
sistance testing, because the K65R mutation may have already
emerged in those patients. Moreover, we included only resis-
tance tests that had been performed after ample exposure to
TDF, to allow for selection of the K65R mutation, which can
occur as early as after 12 weeks of treatment [3, 6, 23]. Thus,
we considered only tests that were performed after 90 days
of continuous therapy with TDF or, in cases in which patients
already had exposure to TDF, tests done after 30 days of con-
tinuous treatment with the current regimen and 90 days of
prior cumulative treatment with TDF. Only the first test per
patient fulfilling all inclusion criteria was considered.
Throughout this project, virological failure was defined as
an on-treatment HIV RNA level 1500 copies/mL after 180
days of continuous treatment. Moreover, the study baseline was
set at the start of the TDF-containing regimen for which a
genotypic test was available, which did not necessarily corre-
spond with the initiation of TDF.
Furthermore, we retrieved all available resistance tests con-
ducted before the study baseline for included patients. The
resistance database was complemented by retrospective se-
quencing of the virus from frozen plasma samples in the SHCS
repository (full protease gene and codons 29–225 of the RT
gene) [24]. For this, plasma specimens with a viral load 1250
copies/mL were selected according to a predefined algorithm.
Initially, we searched for specimens obtained while the partic-
ipant was receiving treatment with TDF, ddI, or ABC. If none
were available, we further considered plasma samples taken near
the time of the latest virological failure events before the study
baseline. For the remaining patients, we obtained pretreatment
specimens.
Analysis. Patients were grouped according to the presence
or absence of the K65R mutation. With use of the Mann-
Whitney U test for continuous variables and Fisher’s exact test
for categorical variables, as well as univariable and multivariable
logistic regression models, the following factors at the start of
the TDF treatment were compared between the 2 groups: so-
ciodemographic characteristics; presence of TAMs, M184V,
protease inhibitor (PI) mutations, or nonnucleoside reverse-
transcriptase inhibitor in (NNRTI) mutations; HIV-1 subtype;
previous exposure to ddI, ABC, or TDF; number of previous
regimens; number of previous virological failures; and current
treatment with ddI, ABC, NNRTI, PI, or thymidine analogues.
In a secondary analysis, we further included viral factors po-
tentially linked to the presence or absence of TAMs (RT mu-
tations 214L and 83K) [25–27].
Associations of K65R with other RT mutations from on-
treatment tests were assessed using Fisher’s exact test, with
adjustments for multiple testing (0.05 false-discovery rate, by
the Benjamini-Hochberg method) [28]. Mutations selected for
analysis were based on the 2006 International AIDS Society–
USA drug mutation list [29]. TAMs were stratified into TAMs
group 1 (M41L, L210W, and T215Y) and TAMs group 2 (D67N,
K70R, T215F, K219E, and K219Q).
We compared treatment response to the first therapy (after
treatment with TDF) between the K65R and the wild-type
groups by calculating the group-wise proportion of individuals
attaining an HIV RNA level !50 copies/mL at week 12 or week
24. If such salvage treatment lasted !12 weeks, the patient was
included in the week 12 analysis but was excluded from the
week 24 analysis.
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Figure 1. Flow chart of patient selection and calculation of prevalence of K65R. ABC, abacavir; ART, antiretroviral therapy; GRT, genotypic resistance
test, TDF, tenovofir; ddI, didanosine.
Statistical analyses were performed with Stata 10 SE software
(StataCorp). All tests of significance were 2 sided, and P values
!.05 were considered to be statistically significant.
RESULTS
Prevalence of K65R. By July 2007, the SHCS drug resistance
database contained samples from 70 patients with the K65R
mutation, corresponding to a cumulative prevalence of 2.2%
among all SHCS participants with at least 1 genotypic resistance
test (figure 1). We found no time trend for the prevalence of
K65R for the period 2002–2007 ( , by Cochran-Ar-Pp .154
mitage test; data not shown), although we noted an increase
in prevalence, from 0.7% in 2002 to 2.0% in 2003, that co-
incided with the registration of TDF in Switzerland. Among
patients with a resistance test performed on TDF, the prevalence
of K65R was 10.1%.
Clinical and genotypic correlates at baseline with K65R.
In this analysis, we included 222 patients (42 in the K65R group
and 180 in the wild-type group). For 32 (14.4%) of those 222
patients, the treatment under consideration was their first an-
tiretroviral therapy (table 1). A total of 71 patients (32.0%) had
already been exposed to TDF during a previous treatment pe-
riod without virological failure (median exposure time, 5.7
months [interquartile range, 2.9–11.3 months]). Genotypic re-
sistance tests performed before the start of the TDF-containing
regimen were available for 186 of 222 patients (in the K65R
group, 36 [85.7%]; in the wild-type group, 152 [84.4%]). No
K65R mutation was detected in those samples.
Among 36 patients in the K65R group with a genotypic
resistance test before the start of TDF, 1 (2.8%) harbored viruses
with TAMs group 2, compared with 30 (19.7%) in the wild-
type group (table 1). No such difference was observed for TAMs
group 1, which were detected in 4 patients (11.1%) from the
K65R group and 25 patients (16.4%) from the wild-type group.
Moreover, patients of the K65R group were more frequently
receiving first-line therapy (28.6%) than were patients in the
wild-type group (11.1%), and a higher proportion was receiving
combination therapy containing ddI (59.5% vs. 37.8% in wild-
type group). Of note, no instance of K65R was observed in 25
patients who received zidovudine or stavudine with TDF. Ther-
apies are detailed in table 2. We identified strong associations
of K65R with the additional drug class included in combination
Table 1. Characteristics at the start of the tenovofir-containing regimen (baseline).
Characteristic
Mutation type
P
K65R
(n p 42)
Wild type
(n p 180)
Female sex 16 (38.1) 58 (32.2) .472
Age, median years (IQR) 40.5 (37–47) 41 (37–46.5) .759
Mode of HIV acquisition
Heterosexual intercourse 16 (38.1) 74 (41.1) .871
Injection drug use 10 (23.8) 40 (22.2)
Male homosexual intercourse 14 (33.3) 61 (33.9)
Other 2 (4.8) 5 (2.8)
Ethnicity
White 33 (78.6) 137 (76.1) .656
Black 6 (14.3) 34 (18.9)
Other 3 (7.1) 9 (5)
HIV subtype
B 33 (78.6) 134 (74.4) .124
CRF01_AE 2 (4.8) 1 (0.6)
C 2 (4.8) 8 (4.4)
Other 5 (11.9) 37 (20.6)
Nadir CD4 cell count, median (IQR)a 132 (60–241) 142 (50–220) .980
Baseline CD4 cell count, median (IQR)a 191 (90–288) 266 (153–407) .016
Baseline log10 HIV RNA level, median (IQR)
a 4.6 (2.3–5.3) 3.8 (1.2–5.2) .095
Previous CDC C event 30 (71.4) 108 (60) .216
Baseline mutation
Baseline test available 36 (85.7) 152 (84.4) 1.000
TAMs (any) 5 (13.9) 45 (29.6) .061
TAMs group 1b 4 (11.1)b 25 (16.4) .608
TAMs group 2c 1 (2.8)c 30 (19.7) .011
NNRTI mutations 9 (25) 30 (19.7) .497
PI mutations 4 (11.1) 31 (20.4) .241
RT184V/I 11 (30.6) 54 (35.5) .698
RT214L 7 (19.4) 36 (23.7) .665
RT83K 10 (27.8) 31 (20.4) .371
On first-line antiretroviral therapy 12 (28.6) 20 (11.1) .007
Current treatment, combined with tenofovir
NNRTI 38 (90.5) 56 (31.1) .000
PI 0 (0) 108 (60) .000
Didanosine 25 (59.5) 68 (37.8) .014
Lamivudine or emtricitabine 17 (40.5) 99 (55) .122
Abacavir 3 (7.1) 18 (10) .772
Zidovudine or stavudine 0 (0) 25 (13.9) .006
195% Adherentd 13 (41.9) 82 (50) .439
Treatment historye
Previous regimens, median no. (IQR) 4.5 (3.0–7.0) 5.0 (3.0–7.0) .794
Previous exposure to didanosine or abacavir 17 (56.7) 93 (58.1) .882
Previous exposure to tenofovir 9 (30.0) 62 (38.8) .363
Experienced previous virological failure(s)
0 failure 16 (53.4) 81 (50.6) .745
1 failure 10 (33.3) 56 (35.0)
2 failures 4 (13.3) 23 (14.4)
Virological failure with treatment of zidovudine or stavudine 13 (43.3) 80 (50.0) .503
(continued)
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Table 1. (Continued.)
Characteristic
Mutation type
P
K65R
(n p 42)
Wild type
(n p 180)
Duration of previous exposure to zidovudine or stavudine, median years (IQR) 2.7 (1.1–5.3) 3.6 (1.0–6.3) .364
Virological failures on NNRTI 2 (6.7) 15 (9.4) .633
Virological failures on lamivudine 11 (36.7) 73 (45.6) .365
NOTE. Data represent no. (%) of patients, unless otherwise indicated. CDC, Centers for Disease Control and Prevention; IQR, interquartile
range; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RT, reverse transcriptase; TAMs, thymidine analogue
mutations.
a Baseline laboratory parameters available for 34 and 179 of the K65R and the wild-type groups, respectively.
b TAMs group 1, any RT gene mutation of the following: 41L, 210W, or 215Y; 3 of 4 present as mixture in K65R group.
c TAMs group 2, any RT gene mutation of the following: 67N, 70R, 215F, 219E, or 219Q; present as mixture in K65R group.
d Adherence measure available only for 31 and 164 of the K65R and the wild-type groups, respectively.
e Comparison only for patients not receiving first-line therapy (30 in the K65R group and 160 in the wild-type group).
Table 2. Antiretroviral therapy combinations with tenofovir.
Treatment combinations including tenofovir
No. (%) of patients
First-line regimens Later regimens
K65R Wild type K65R Wild type
Efavirenz and lamivudine-emtricitabine 5 (36) 9 (64) 2 (17) 10 (83)
Efavirenz and didanosine 0 0 13 (46) 15 (54)
Efavirenz and abacavir 0 0 1 (100) 0
Nevirapine and lamivudine-emtricitabine 4 (100) 0 3 (60) 2 (40)
Nevirapine and didanosine 3 (100) 0 7 (54) 6 (46)
Boosted atazanavir and lamivudine-emtricitabine 0 0 0 18 (100)
Lopinavir and lamivudine-emtricitabine 0 6 (100) 0 10 (100)
Lopinavir and didanosine 0 1 (100) 0 12 (100)
Other NNRTI and NRTI 0 0 0 7 (100)
Other boosted PI and NRTI 0 0 0 36 (100)
Other unboosted PI and NRTI 0 0 0 13 (100)
3-Class combination (PI, NNRTI, and NRTI) 0 0 0 4 (100)
Single-class NRTI 0 4 (100) 4 (17) 20 (83)
Other 0 0 0 7 (100)
NOTE. Percentages were calculated on the basis of the number of patients on a specific regimen, stratified
by the 2 treatment groups (patients receiving first-line therapy and patients receiving later treatments). NNRTI,
nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease
inhibitor.
therapy other than NRTIs. No instance of K65R emergence was
observed for treatments including PI. Conversely, 91% of pa-
tients in the K65R group were receiving a combination therapy
with NNRTIs. Accordingly, use of NNRTI arose as the most
predictive factor associated with the emergence of K65R in a
multivariable logistic regression analysis (OR, 23.6; 95% CI,
7.3–76.3) (table 3). Other associations observed in this model
were treatment with first-line therapy (OR, 3.6; 95% CI, 1.1 to
12.2) or treatment with combination therapy containing ddI
(OR, 3.6; 95% CI, 1.3–9.9). No association of K65R with HIV
subtype C was observed [30, 31].
Other RT mutations associated with K65R. We performed
2 analyses for the identification of mutational associations of
RT mutations with K65R. First, we considered only the 222
genotypic tests performed while patients were receiving treat-
ment with TDF (cross-sectional approach); later, we also con-
sidered all preceding resistance tests, if available, assuming that
all mutations ever detected before the start of the TDF-con-
taining regimen would still be present at time of resistance
testing during treatment with TDF (cumulative approach; data
not shown). A comparison of these 2 approaches allowed us
to draw conclusions about the viral evolution of HIV-1 within
patients.
On the basis of unadjusted P values !.05 from the cross-
sectional analysis, we identified 4 NNRTI mutations (L100I,
K103N, G190S, and Y181C) that were more frequently observed
in the K65R group and 3 TAMs (M41L, D67N, and T215Y)
that were much rarer or absent in the K65R group (table 4).
Table 3. Factors associated with the presence of K65R in univariable and multivariable
logistic regression analyses ( ).np 222
Variable(s)
ORa (95% CI)
Univariable Multivariable
Baseline mutations
TAMs group 1 presentb 0.63 (0.21–1.95) 1.11 (0.20–6.03)
No TAMs group 1 present 1 (Reference) 1 (Reference)
No baseline resistance test 0.85 (0.32–2.23) 0.79 (0.19–3.33)
TAMs group 2 presentc 0.12 (0.02–0.92) 0.07 (0.01–0.64)
No TAMs group 1 present 1 (Reference) 1 (Reference)
No baseline resistance test 0.75 (0.29–1.96) Not doned
NNRTI mutations present 1.36 (0.58–3.18) …
No NNRTI mutations present 1 (Reference) …
No baseline resistance test 0.97 (0.37–2.57) …
PI mutations present 0.49 (0.16–1.48) …
No PI mutations present 1 (Reference) …
No baseline resistance test 0.81 (0.31–2.12) …
Female sex 1.29 (0.64–2.60) 2.43 (0.71–8.33)
Age, years, per year increase 1.00 (0.97–1.04) 1.02 (0.97–1.07)
Mode of HIV acquisition
Heterosexual contact 1 (Reference) 1 (Reference)
Injection drug use 1.16 (0.48–2.78) 3.08 (0.80–11.89)
Homosexual bisexual contact 1.06 (0.48–2.35) 2.30 (0.60–8.74)
Other 1.85 (0.33–10.40) 0.66 (0.06–7.25)
Previous CDC stage C event 1.67 (0.80–3.47) 2.87 (1.05–7.84)
Baseline CD4 cell count, per 10-cell increase 0.85 (0.71–1.02) …
Baseline log10 HIV RNA level, per log increase 1.14 (0.97–1.35) …
Ethnicity
White 1 (Reference) 1 (Reference)
Black 0.73 (0.28–1.89) 0.96 (0.15–6.18)
Other 1.38 (0.35–5.40) 0.74 (0.08–7.12)
HIV subtype …
B 1 (Reference) …
CRF01_AE 8.12 (0.71–92.29) 27.08 (0.57–1,282)
C 1.02 (0.21–5.01) 0.94 (0.09–9.45)
Other 0.55 (0.20–1.50) 0.64 (0.10–4.15)
Adherence
!95% 1.38 (0.64–3.01) …
95% 1 (Reference) …
No information available 4.34 (1.65–11.39) …
On first-line antiretroviral therapy 3.20 (1.42–7.23) 3.64 (1.08–12.24)
Current treatment, in combination with tenofovir
Zidovudine or stavudinee 0.11 (0–0.62) Not done
Lamivudine 0.56 (0.28–1.10)
Abacavir 0.69 (0.19–2.47)
Didanosine 2.42 (1.22–4.81) 3.62 (1.32–9.94)
NNRTI 21.04 (7.16–61.79) 23.59 (7.29–76.28)
PIe 0.01 (0–0.06) Not done
Previous exposure to didonasine or abacavir 0.64 (0.32–1.26) …
Previous exposure to tenofovir 0.52 (0.23–1.15) …
Previous failure event(s) …
No previous virological failure 1 (Reference) …
1 Previous virological failure 0.64 (0.29–1.42) …
2 Previous virological failures 0.63 (0.20–1.96) …
(continued)
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Table 3. (Continued.)
Variable(s)
ORa (95% CI)
Univariable Multivariable
Previous virological failure on lamivudine 0.52 (0.25–1.10) …
Previous virological failure on NNRTI 0.55 (0.12–2.50) …
Previous virological failure on zidovudine or stavudine 0.56 (0.27–1.15) …
NOTE. CDC, Centers for Disease Control and Prevention; NNRTI, nonnucleoside reverse-transcriptase inhib-
itor; PI, protease inhibitor; RT, reverse transcriptase; TAMs, thymidine analogue mutations.
a By logistic regression analysis.
b TAMs group 1, any RT gene mutation of the following: 41L, 210W, or 215Y.
c TAMs group 2, any RT gene mutation of the following: 67N, 70R, 215F, 219E, or 219Q.
d Not included in multivariable model because of collinearity.
e OR from exact logistic regression. For computational reasons, only univariable estimates could be obtained.
After adjustment for multiple testing, only T215Y, G190S, and
Y181C reached statistical significance (table 4). The latter 2
mutations, together with K65R, were identified as a distinct
mutational pattern in 6 patients treated with EFV and TDF.
The cumulative approach confirmed that G190S and Y181C
were not present at study baseline and must have been cose-
lected with K65R (data not shown).
In a secondary analysis, we investigated associations of
grouped TAMs with K65R (TAMs group 1 or TAMs group 2),
again using the cross-sectional and the cumulative methods. In
the cross-sectional analysis, TAMs group 1 were found in 2
patients from the K65R group and in 41 patients from the wild-
type group. In contrast, the cumulative approach showed that
5 patients in the K65R and 44 patients in the wild-type group
harbored viruses with TAMs group 1. TAMs group 2 were
detected in 1 and 45 patients from the K65R and the wild-type
group, respectively, with the cross-sectional method and 2 and
53 patients, respectively, with the cumulative approach. Thus,
viruses of 4 patients with K65R had lost TAMs between the
baseline sample and the detection of the K65R mutation (3
with TAMs group 1 and 1 with TAMs group 2). Three of these
patients had extended treatment breaks, with a range of 1.5–
4.8 years, before beginning the TDF-containing regimen. The
fourth patient had a 1-year respite from therapy but resumed
treatment with stavudine, ddI, and nevirapine and achieved
viral suppression before switching to therapy with TDF. Taken
together, virus populations these 4 patients demonstrated shifts
toward wild-type status once selection pressure by antiretroviral
drugs was removed.
Clinical outcomes of TDF-containing regimens. We fur-
ther studied treatment outcomes of the TDF-containing regi-
mens and of continuation of drug histories (figure 1). As of
the database closure for this analysis, 168 patients had stopped
the TDF-containing regimen. For 112 patients—that is, 33 pa-
tients (78.6%) from the K65R group and 79 patients (43.9%)
from the wild-type group—immunologic or virologic failure
was cited as the reason for stopping. Antiretroviral therapy–
related toxicities were reported as being the cause for stopping
the TDF-containing regimen in 16 patients (8.9%) of the wild-
type group, and 1 patient of the K65R group died while being
treated with TDF. All other stop reasons (for 6 patients in the
K65R group and for 33 patients in the wild-type group) were
either unknown or not clearly specified.
In total, 154 patients switched to a new therapy (from the
K65R group, 36 patients; from the wild-type group, 118 pa-
tients). In the K65R group, 31 patients switched to a PI, of
whom 26 patients received a ritonavir boosted regimen and 23
had a regimen with a combination of zidovudine or stavudine.
Moreover, 4 patients switched to a single-class NRTI therapy
with ABC, and 1 patient continued with NNRTI treatment but
replaced TDF with a different NRTI. At week twelve, 38.9% of
the K65R group and 41.5% of the wild-type group showed a
virological response to those new treatments ( , byPp .848
Fisher’s exact test) (figure 1). At week 24, virological response
was 44.1% for patients with K65R and 51.9% in the wild-type
group ( , by Fisher’s exact test). An intent-to-treat ap-Pp .556
proach yielded similar results (data not shown). We repeated
these analyses with logistic regression models adjusted for base-
line HIV RNA level, the inclusion of enfuvirtide, and the num-
ber of active drugs in the new regimen with a genotypic sen-
sitivity score !15, as calculated by the Stanford algorithm on
the basis of cumulative drug resistance information [32]. We
found no evidence that patients harboring viruses with the
K65R mutation had a worse treatment outcome at week 12
(OR, 1.2; 95% CI, 0.50–2.70) and week 24 (OR, 0.92, 95% CI,
0.40–2.12), when compared with the wild-type group.
DISCUSSION
Of 222 patients receiving a TDF-containing antiretroviral treat-
ment, combinations of TDF with NNRTIs and/or ddI were
highly associated with the emergence of the K65R mutation.
In contrast, not a single patient receiving TDF combined with
PI or thymidine analogues harbored viruses with the K65R
Table 4. Reverse-transcriptase mutations associated with K65R in genotypic resistance tests
performed on combination therapy with tenofovir.
Mutation
Proportion of patients
with mutation (%)
P a Critical P b SignificantK65R Wild type
NNRTI
100I 6/40 (15) 5/137 (3.6) .018 .009
103N 16/40 (40) 31/137 (22.6) .041 .014
106M 2/40 (5) 2/137 (1.5) .220 .027
106A 1/40 (2.5) 0/137 (0) .226 .029
108I 3/40 (7.5) 7/137 (5.1) .696 .042
181Cc 19/40 (47.5) 7/137 (5.1) .000 .002 Yes
188L 1/40 (2.5) 4/137 (2.9) 1 .044
188C 2/40 (5) 1/137 (0.7) .128 .018
188H 0/40 (0) 2/137 (1.5) 1 .045
190A 6/40 (15) 8/137 (5.8) .090 .015
190S 8/40 (20) 2/137 (1.5) !.001 .003 Yes
190E 1/40 (2.5) 1/137 (0.7) .402 .030
225H 1/40 (2.5) 1/137 (0.7) .402 .032
TAMs group 1
41L 1/30 (3.3) 32/155 (20.6) .020 .011
210W 0/30 (0) 15/155 (9.7) .136 .020
215Y 0/30 (0) 29/155 (18.7) .005 .006 Yes
Any 1/30 (3.3) 37/155 (23.9) .012 .008
TAMs group 2
67N 1/30 (3.3) 31/155 (20) .032 .012
70R 1/30 (3.3) 20/155 (12.9) .207 .023
215F 0/30 (0) 12/155 (7.7) .220 .024
219Q 0/30 (0) 12/155 (7.7) .220 .026
219E 0/30 (0) 6/155 (3.9) .592 .035
Any 1/30 (3.3) 42/155 (27.1) .004 .005 Yes
NRTI (other than TAMs)
115F 2/42 (4.8) 1/180 (0.6) .093 .017
116Y 0/42 (0) 1/180 (0.6) 1 .047
70Ed 2/42 (4.8) 7/180 (3.9) .680 .039
151M 0/42 (0) 1/180 (0.6) 1 .048
62V 2/42 (4.8) 2/180 (1.1) .163 .021
74V 2/42 (4.8) 7/180 (3.9) .680 .041
184V/I 14/40 (35) 59/168 (35.1) 1 .050
Other (not drug-resistance related)
214L 7/42 (16.7) 38/180 (21.1) .671 .038
68G 2/42 (4.8) 5/180 (2.8) .619 .036
83K 9/42 (21.4) 30/180 (16.7) .501 .033
NOTE. Percentages were calculated on the basis of the number of patients in each group who were ever exposed
to the respective drug class (e.g., NNRTI, thymidine analogues, or NRTIs without thymidine analogues). NNRTI, non-
nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; RT, reverse transcriptase;
TAMs, thymidine analogue mutations.
a By Fisher’s exact test.
b Benjamini-Hochberg critical value, with the assumption of a false-discovery rate of 0.05.
c For 6 patients treated with efavirenz, a distinct mutational pattern consisting of G190S and Y181C was observed,
which always appeared in combination with K65R. Those patients are all infected with subtype B viruses.
d In the 2 patients from the K65R group, K65R and K70E were present as mixtures.
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mutation. The presence of 1 or several mutations of the TAMs
group 2 (D67N, K70R, 215F, 219Q, and 219E) at the start of
the TDF-containing regimen appeared to have a protective ef-
fect against the emergence of K65R. Among 4 patients who
had lost TAMs because of extended therapy interruptions, we
noted that K65R could still be selected, despite the likely pres-
ence of TAMs in minor viral populations. However, in none
of these patients did the TAMs reemerge, which further sup-
ports the hypothesis that TAMs and the K65R mutation cannot
exist on the same genome [17].
We further observed a previously undescribed pattern of
NNRTI mutations (G190S and Y181C) and K65R in EFV-
treated patients. Those NNRTI-specific mutations were not
present at the start of combination therapy with TDF and EFV
and must have been coselected with K65R.
Moreover, we investigated therapy success of the subsequent
treatment among patients who had stopped the TDF-contain-
ing regimen and who switched to a new regimen. We did not
observe statistically significant differences between the K65R
group and the wild-type group in the proportion of patients
with HIV RNA levels !50 copies/mL after 12 weeks and 24
weeks of continuous treatment. At week 24, approximately one-
half of the patients reached plasma viremia levels !50 copies/
mL, a result that is in line with or even better than salvage
trials before tipranavir, darunavir, and raltegravir became widely
available [33–37]. Taking due account of small sample size and
short follow-up period, these results suggest that patients who
harbor viruses with the K65R mutation are as likely to attain
viral loads !50 copies/mL as are patients with K65WT.
This study provides support for a protective effect of TAMs—
and in particular TAMs goup 2—against the emergence of
K65R. Thus, it is not surprising that patients who initiate their
first antiretroviral therapy with combination therapy that in-
cludes TDF are at a higher risk of acquiring K65R if their
antiretroviral therapy fails, given the fact that the prevalence
of transmitted resistance and TAMs remains ∼10% in Swit-
zerland [38]. In contrast, patients with extended treatment his-
tories and previous virological failure are more likely to harbor
viruses carrying TAMs [V.v.W. and H.F.G., unpublished data].
Why were there no TAMs at study baseline in the pretreated
patients from the K65R group? Extended treatment interrup-
tions might be one answer, as case reviews from 4 patients
indicated. Furthermore, we investigated viral factors (RT mu-
tations 214L and 83K), which have recently been linked with
the absence of TAMs in pretreated patients [25, 26], but the
analysis results were not conclusive.
We noted that the additional drugs other than TDF that were
included in combination therapy might play an important role
in the emergence of K65R. Combinations of TDF and ddI
appear to be problematic, because ddI and TDF share the same
mutational pathway for selection of K65R.
Moreover, whereas K65R was absent in patients treated with
PI, the use of EFV or nevirapine was highly associated with
the emergence of K65R. This may be due to synergistic fitness
effects with NNRTI-induced mutations on the reverse tran-
scriptase, as our observation of the previously unreported
K65R/G190S/Y181C mutational pattern in 6 EFV-treated pa-
tients suggests. Because G190S is associated with a high fitness
cost relative to the wild type [39], K65R and/or Y181C may
compensate for this. Such fitness synergies have been described
between the NRTI mutation L74V and the NNRTI mutations
K103N and L100I [40].
Alternatively, K65R may occur preferentially with treatment
with EFV or nevirapine compared with PI regimens because
only 1 mutation is required to confer full resistance against
those NNRTIs, whereas PIs often retain residual activity against
HIV-1 despite the presence of PI mutations. Thus, in combi-
nation therapy with TDF and NNRTI, insufficient intracellular
concentrations of combination therapy with TDF can quickly
lead to viral breakthrough and full NNRTI resistance, followed
by the emergence of additional mutations [3, 23]. In line with
this argument, patients with no previous virological failure who
were treated with an NNRTI and TDF ( ) generally hadnp 53
viruses with more resistance mutations (median, 3 mutations;
interquartile range, 1–4 mutations]) than did patients who re-
ceived therapy with a combination of TDF and a ritonavir-
boosted PI ( ) (median, 0 mutations; interquartile range,np 44
0–1 mutation; data not shown).
Because these data stem from a representative cohort study
reflecting current clinical practice, we consider the conclusions
to be clinically relevant. The study has limitations, however.
We have compared patients with highly diverse treatment his-
tories and who were selected with no randomization; therefore,
we cannot exclude the possibility that there were unmeasured
confounding factors. Patients receiving tenofovir had to have
a genotypic drug resistance test available, implying a selection
bias. However, during this study, genotypic resistance testing
in patients with failing antiretroviral treatment was already clin-
ically routine [33]. The time point of genotypic testing might
also have confounded our results, in particular for the baseline
resistance testing. Predefined stringent selection criteria likely
have minimized the impact on confounding. We also noted no
systematic effect of timing of resistance testing on our results
(data not shown).
Our findings suggest that optimal future treatment regimens
should avoid combining EFV or nevirapine with TDF and ad-
ditional NRTI drugs that favor the selection of the K65R mu-
tation, such as ddI or ABC. Furthermore, the highly protective
effect of boosted PIs and the observed antagonistic effects of
TAMs on the emergence of K65R suggest a potentially pivotal
role of combining thymidine analogues, boosted PIs, and te-
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nofovir in salvage situations. This strategy should be explored
in prospective studies.
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